Feraccru® / Accrufer® : A treatment for iron deficiency with or without anaemia
Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s.
In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2024 – it will be marketed as Accrufer®.
We also have an exclusive licence agreement with ASK Pharm, who will lead development and commercialisation in China.
Find out more